Sign In
Buy SIBN
$15.84
+0.630 (+4.14%)
At Close: Jun 18, 2026
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
06:40pm, Monday, 24'th Feb 2025
Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.27 per share a year ago.
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance
04:09pm, Monday, 24'th Feb 2025
Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024
Bruker Appoints Laura Francis to its Board of Directors
08:00am, Friday, 21'st Feb 2025
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent dir
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Monday, 17'th Feb 2025
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025
04:09pm, Monday, 03'rd Feb 2025
SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial resul
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade
10:55am, Thursday, 12'th Dec 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positi
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
10:55am, Tuesday, 26'th Nov 2024
The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
04:09pm, Wednesday, 20'th Nov 2024
SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be parti
SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript
10:42pm, Tuesday, 12'th Nov 2024
SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Offi
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
06:26pm, Tuesday, 12'th Nov 2024
Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago.
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance
04:09pm, Tuesday, 12'th Nov 2024
SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarte
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™
08:30am, Tuesday, 05'th Nov 2024
The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures The i
Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength?
04:35am, Wednesday, 30'th Oct 2024
Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024
04:09pm, Tuesday, 22'nd Oct 2024
SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial resul
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device
01:20pm, Monday, 14'th Oct 2024
SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.
